Inmune Stock News

INmune Bio Inc (NASDAQ:INMB)’s share price gapped up prior to trading on Tuesday after Roth Capital raised their price target on the stock from $13.00 to $26.00. The stock had previously closed at $

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT...

Inmune Bio stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer's treatment. The drug targets inflammation in the brain.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) * Altimmune Inc (NASDAQ: ALT) (announced positive pre

Stocks Analysis by Harry Boxer covering: KB Home, Vaxart Inc, Novavax Inc, Altimmune Inc. Read Harry Boxer's latest article on Investing.com

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memoryLA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Compa

LA JOLLA, Calif., July 09, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the.

LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and...

By Anita Dushyanth, PhD NASDAQ:INMB | NASDAQ:NTRP | TSX:PMN.TO Rethinking the approach to treat Alzheimer’s disease Both scientists and physicians are still wrestling with the idea of how to identif

INmune Bio (NASDAQ:INMB) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the stre

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that t

City of Hope’s physician-scientists and basic scientists are using their expertise to attack the deadly coronavirus on multiple research fronts.

INmune Bio, Inc. (INMB) (the “Company”), a clinical-stage immunology company focused on  developing treatments that harness the patient’s innate immune system to fight disease, announced public

INmune Bio, Inc. (NASDAQ:INMB) Q1 2020 Earnings Conference Call May 14, 2020 4:30 P.M. ET Company Participants RJ Tesi - Co-Founder and Chief Executive Officer

LA JOLLA, Calif., May 14, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.